Peringatan Keamanan

In addition to its intended cytotoxic effects, tasonermin produces secondary adverse effects.

Studies in mice, rats, dogs, monkeys, and rabbits observed hematological changes including anemia, increased hematocrit, and changes in leukocyte and platelet counts dependent on species and treatment duration FDA Label.

Tasonermin also produces decreases in blood pressure. Increases in heart rate and reductions in cardiac contractility have been noted in some studies.

Increased liver enzymes suggest altered liver function as a result of tasonermin administration. Changes in kidney function have also been observed including increased water and sodium excretion as well as increased serum urea and creatinine.

The only study to determine a no observable adverse effect level found the value to be 0.1 ?g/kg in monkeys during a 7-day course of tasonermin.

Tasonermin

DB11626

biotech approved

Deskripsi

Tasonermin is recombinant soluble form tumor necrosis factor α produced via Escherichia coli cell culture. It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma of the limbs as the product Beromun. It is administered with DB01042 via mild hyperthermic isolated limb perfusion.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Tasonermin has a terminal half life of 20-30 min at doses of 150 ?g/m² [L1339]. This value increases as dosage increases.
Volume Distribusi The estimated volume of distribution varies with the dose administered with intravenous doses of 35 ?g/m² and 150 ?g/m² producing values of 55 L and 17 L respectively [L1339].
Klirens (Clearance) Clearance was estimated to be 2 L/min and 0.5 L/min after intravenous doses of 35 ?g/m² and 150 ?g/m² respectively [L1339]. This value decreases as dosage increases.

Absorpsi

No absorption data is available. No enteral route formulation exists for tasonermin.

Metabolisme

No metabolism data is available. Tasonermin is assumed to be broken down similarly to other proteins in systemic circulation.

Rute Eliminasi

No data is available on route of elimination.

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

Tumor necrosis factor receptor superfamily member 1A TNFRSF1A
Tumor necrosis factor receptor superfamily member 1B TNFRSF1B

Referensi & Sumber

Artikel (PubMed)
  • PMID: 7542214
    Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995 Jul;9(10):899-909.
  • PMID: 12655295
    Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 2003 Jan;10(1):45-65. doi: 10.1038/sj.cdd.4401189.
  • PMID: 19118493
    Zhang H, Park Y, Wu J, Chen Xp, Lee S, Yang J, Dellsperger KC, Zhang C: Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009 Feb;116(3):219-30. doi: 10.1042/CS20080196.
  • PMID: 21275341
    Pate M, Damarla V, Chi DS, Negi S, Krishnaswamy G: Endothelial cell biology: role in the inflammatory response. Adv Clin Chem. 2010;52:109-30.
Textbook
  • ISBN: 978-1-25-958473-2
    Brunton LL, Hilal-Dandan R, Knollmann BC. eds (2018). Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Beromun
    Injection, powder, for solution • 1 mg/5ml • - • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul